文献速递甲状腺与浅表介入US

超声引导下经皮微波消融治疗胸骨后甲状腺肿的初步经验

Ultrasound-Guided Percutaneous Microwave Ablation for Substernal Goiter: Initial Experience.
PubMed 文献 · J Ultrasound Med · 2019-03-21

本研究于2017年4月至12月对10例胸骨后甲状腺肿患者行超声引导下微波消融,随访至少3个月,评估症状缓解、美容分级改善及结节体积缩小率(VRR)。3个月时结节体积由52.9±27.9 mL降至17.5±9.5 mL(P<.05),平均VRR为66.7%±7.1%,症状评分和美容分级均显著下降,未观察到并发症。消融后1天消融部分与结节比值较高可预测较高的3个月VRR(Spearman r=0.646;P=.044)。

要点

  • 微波消融后3个月结节平均体积缩小率(VRR)为66.7%±7.1%,结节体积由52.9±27.9 mL降至17.5±9.5 mL(P<.05)。
  • 消融后1天消融部分与结节比值较高与较高的3个月VRR相关(Spearman r=0.646;P=.044)。
  • 术后3个月症状评分和美容分级均显著下降,未观察到并发症或意外副作用。

核心结论

  • 初步结果支持微波消融对胸骨后甲状腺肿局部控制的有效性和安全性,该技术可应用于不适合手术的特定胸骨后甲状腺肿患者。

研究设计与样本

  • 单臂初步研究,2017年4月至2017年12月纳入10例胸骨后甲状腺肿患者行超声引导下微波消融,随访至少3个月观察疗效和并发症。

关键影像表现/征象

  • 微波消融后3个月结节体积由52.9±27.9 mL(范围23.7-122.6 mL)降至17.5±9.5 mL(P<.05)。
  • 平均3个月VRR为66.7%±7.1%。
  • 消融后1天消融部分与结节比值较高可预测较高的3个月VRR(Spearman r=0.646;P=.044)。
  • 平均症状评分由4.5±1.7降至1.5±1.0(P=.005),美容分级由3.3±0.5降至2.2±0.4(P=.004)。
  • 未观察到并发症或意外副作用。

临床应用与阅片要点

  • 作者认为微波消融可用于不适合手术的特定胸骨后甲状腺肿患者的局部控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To preliminarily evaluate the safety, effectiveness, and feasibility of microwave ablation (MWA) for substernal goiter (SSG) in select patients and to provide a relevant treatment reference for further studies.

METHODS: From April 2017 to December 2017, 10 patients with SSG were treated by MWA. All patients were followed for at least 3 months to observe the therapeutic effects and complications. Therapeutic effects were assessed at follow-up for the relief of patients' symptoms, resolution of the cosmetic grade, and volume reduction rate (VRR) of SSG. Possibly related factors for the 3-month VRR of the nodules were analyzed.

RESULTS: The study included 9 female patients and 1 male patient with a mean age ± SD of 56.8 ± 10.1 years (range, 34-70 years). The mean volume of the nodules was 52.9 ± 27.9 mL (range, 23.7-122.6 mL). The nodule volume was significantly reduced at the 3-month follow-up (17.5 ± 9.5 mL; P < .05). The mean 3-month VRR of the index nodule was 66.7% ± 7.1%. A higher ablated portion-to-nodule ratio 1 day after MWA predicted a higher 3-month VRR (Spearman r = 0.646; P = .044). The mean symptom score (from 4.5 ± 1.7 to 1.5 ± 1.0; P = .005) and cosmetic grade (from 3.3 ± 0.5 to 2.2 ± 0.4; P = .004) declined significantly 3 months after the procedure. No complications or unexpected side effects were observed.

CONCLUSIONS: Our preliminary results support the effectiveness and safety of MWA for local control of SSG. This technology can be applied in select patients with SSG who are ineligible for surgery.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Cui R, Yu J, Han ZY, et al. Ultrasound-Guided Percutaneous Microwave Ablation for Substernal Goiter: Initial Experience. J Ultrasound Med. 2019. PMID: 30900322. doi:10.1002/jum.14992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。